Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients

Journal of Immunology

Volumn 188, Issue 11, 2012, Pages 5448-5458

  Bergenfelz, Caroline ^a   Medrek, Catharina ^a   Ekström, Elin ^a   Jirström, Karin ^a   Janols, Helena ^a   Wullt, Marlene ^a   Bredberg, Anders ^a   Leandersson, Karin ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; TOLL LIKE RECEPTOR 4; WNT5A PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; EPITHELIUM CELL; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCYTE; NEGATIVE FEEDBACK; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYELONEPHRITIS; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UROSEPSIS;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COHORT STUDIES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; INFLAMMATION; MACROPHAGES; MONOCYTES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; SEPSIS; WNT PROTEINS;

EID: 84862066130     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103378     Document Type: Article

References (44)

1. Bianchi, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81: 1-5. (Pubitemid 46028489)
2. Erridge, C. 2010. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J. Leukoc. Biol. 87: 989-999.
3. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
4. Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M. G. Totaro, M. Rimoldi, S. K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18: 349-355.
5. Biswas, S. K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487.
6. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
7. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25: 2546-2553. (Pubitemid 47041228)
8. -/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70: 4335-4345.
9. low/- monocytes in prostate cancer. Prostate 70: 443-455.
10. O'Neill, L. A., and A. G. Bowie. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7: 353-364. (Pubitemid 46674493)
11. Sen, R., and S. T. Smale. 2010. Selectivity of the NF-κB response. Cold Spring Harb. Perspect. Biol. 2: a000257.
12. Ziegler-Heitbrock, L. 2001. The p50-homodimer mechanism in tolerance to LPS. J. Endotoxin Res. 7: 219-222. (Pubitemid 32894576)
13. Saccani, A., T. Schioppa, C. Porta, S. K. Biswas, M. Nebuloni, L. Vago, B. Bottazzi, M. P. Colombo, A. Mantovani, and A. Sica. 2006. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66: 11432-11440. (Pubitemid 46009975)
14. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166. (Pubitemid 46718400)
15. Porta, C., M. Rimoldi, G. Raes, L. Brys, P. Ghezzi, D. Di Liberto, F. Dieli, S. Ghisletti, G. Natoli, P. De Baetselier, et al. 2009. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. Proc. Natl. Acad. Sci. USA 106: 14978-14983.
16. Sims, G. P., D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle. 2010. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367-388.
17. Zanotti, S., A. Kumar, and A. Kumar. 2002. Cytokine modulation in sepsis and septic shock. Expert Opin. Investig. Drugs 11: 1061-1075.
18. Janols, H., A. Bredberg, I. Thuvesson, S. Janciauskiene, O. Grip, and M. Wullt. 2010. Lymphocyte and monocyte flow cytometry immunophenotyping as a diagnostic tool in uncharacteristic inflammatory disorders. BMC Infect. Dis. 10: 205.
19. Porcheray, F., S. Viaud, A. C. Rimaniol, C. Léone, B. Samah, N. Dereuddre- Bosquet, D. Dormont, and G. Gras. 2005. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 142: 481-489. (Pubitemid 41719844)
20. Chien, A. J., W. H. Conrad, and R. T. Moon. 2009. A Wnt survival guide: from flies to human disease. J. Invest. Dermatol. 129: 1614-1627.
21. Leandersson, K., K. Riesbeck, and T. Andersson. 2006. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res. 34: 3988-3999. (Pubitemid 44391014)
22. Dejmek, J., K. Leandersson, J. Manjer, A. Bjartell, S. O. Emdin, W. F. Vogel, G. Landberg, and T. Andersson. 2005. Expression and signaling activity of Wnt- 5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin. Cancer Res. 11: 520-528. (Pubitemid 40116875)
23. Malhotra, S., and P. W. Kincade. 2009. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 4: 27-36.
24. Staal, F. J., T. C. Luis, and M. M. Tiemessen. 2008. WNT signalling in the immune system: WNT is spreading its wings. Nat. Rev. Immunol. 8: 581-593.
25. Pereira, C., D. J. Schaer, E. B. Bachli, M. O. Kurrer, and G. Schoedon. 2008. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler. Thromb. Vasc. Biol. 28: 504-510.
26. Blumenthal, A., S. Ehlers, J. Lauber, J. Buer, C. Lange, T. Goldmann, H. Heine, E. Brandt, and N. Reiling. 2006. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 108: 965-973. (Pubitemid 44154632)
27. Christman, M. A., II, D. J. Goetz, E. Dickerson, K. D. McCall, C. J. Lewis, F. Benencia, M. J. Silver, L. D. Kohn, and R. Malgor. 2008. Wnt5a is expressed in murine and human atherosclerotic lesions. Am. J. Physiol. Heart Circ. Physiol. 294: H2864-H2870.
28. Sen, M., M. Chamorro, J. Reifert, M. Corr, and D. A. Carson. 2001. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum. 44: 772-781. (Pubitemid 32319769)
29. Pukrop, T., F. Klemm, T. Hagemann, D. Gradl, M. Schulz, S. Siemes, L. Trümper, and C. Binder. 2006. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc. Natl. Acad. Sci. USA 103: 5454-5459.
30. Gordon, M. D., M. S. Dionne, D. S. Schneider, and R. Nusse. 2005. WntD is a feedback inhibitor of Dorsal/NF-κB in Drosophila development and immunity. Nature 437: 746-749. (Pubitemid 41486544)
31. Elkabets, M., A. M. Gifford, C. Scheel, B. Nilsson, F. Reinhardt, M. A. Bray, A. E. Carpenter, K. Jirström, K. Magnusson, B. L. Ebert, et al. 2011. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J. Clin. Invest. 121: 784-799.
32. Meyer, T. P., I. Zehnter, B. Hofmann, J. Zaisserer, J. Burkhart, S. Rapp, F. Weinauer, J. Schmitz, and W. E. Illert. 2005. Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters. J. Immunol. Methods 307: 150-166. (Pubitemid 41817276)
33. Korzeniewski, C., and D. M. Callewaert. 1983. An enzyme-release assay for natural cytotoxicity. J. Immunol. Methods 64: 313-320. (Pubitemid 14243095)
34. Schreiber, E., P. Matthias, M. M. Müller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells. Nucleic Acids Res. 17: 6419. (Pubitemid 19198635)
35. Fan, H., and J. A. Cook. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10: 71-84.
36. Hu, X., J. Chen, L. Wang, and L. B. Ivashkiv. 2007. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J. Leukoc. Biol. 82: 237-243. (Pubitemid 47230632)
37. Hintz, K. A., A. J. Rassias, K. Wardwell, M. L. Moss, P. M. Morganelli, P. A. Pioli, A. L. Givan, P. K. Wallace, M. P. Yeager, and P. M. Guyre. 2002. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up- regulation of the monocyte hemoglobin scavenger receptor CD163. J. Leukoc. Biol. 72: 711-717. (Pubitemid 36277842)
38. Groselj-Grenc, M., A. Ihan, and M. Derganc. 2008. Neutrophil and monocyte CD64 and CD163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes. Mediators Inflamm. 2008: 202646.
39. Goldsmith, M., D. Avni, O. Ernst, Y. Glucksam, G. Levy-Rimler, M. M. Meijler, and T. Zor. 2009. Synergistic IL-10 induction by LPS and the ceramide-1- phosphate analog PCERA-1 is mediated by the cAMP and p38 MAP kinase pathways. Mol. Immunol. 46: 1979-1987.
40. Hansen, C., J. Howlin, A. Tengholm, O. Dyachok, W. F. Vogel, A. C. Nairn, P. Greengard, and T. Andersson. 2009. Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J. Biol. Chem. 284: 27533-27543.
41. Cheon, H., Y. H. Rho, S. J. Choi, Y. H. Lee, G. G. Song, J. Sohn, N. H. Won, and J. D. Ji. 2006. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol. 177: 1092-1100. (Pubitemid 44036612)
42. Rieser, C., C. Papesh, M. Herold, G. Böck, R. Ramoner, H. Klocker, G. Bartsch, and M. Thurnher. 1998. Differential deactivation of human dendritic cells by endotoxin desensitization: role of tumor necrosis factor-alpha and prostaglandin E2. Blood 91: 3112-3117. (Pubitemid 28193858)
43. Deng, J., W. Xia, S. A. Miller, Y. Wen, H. Y. Wang, and M. C. Hung. 2004. Crossregulation of NF-κB by the APC/GSK-3β/β-catenin pathway. Mol. Carcinog. 39: 139-146.
44. Montaner, L. J., R. P. da Silva, J. Sun, S. Sutterwala, M. Hollinshead, D. Vaux, and S. Gordon. 1999. Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-γ or IL-10. J. Immunol. 162: 4606-4613. (Pubitemid 29314860)